A Study to Evaluate the Efficacy and Safety of CREZET Tablet

NCT05889143 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2025-08-24

No results posted yet for this study

Summary

This observation study is to evaluate blood lipid-lowering effects and liver/renal safety, changes in HbA1c and FPG in patients with dyslipidemia who administered CREZET tablets for 24 weeks.

Conditions

  • Dyslipidemias

Interventions

DRUG

Ezetimibe/Rosuvastatin

Patient treated with Crezet Tablet

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • JunYoung Park · Daewoong Pharma

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-24
Primary Completion
2024-12-31
Completion
2026-03-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05889143 on ClinicalTrials.gov